{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:08:34Z","timestamp":1755223714484,"version":"3.43.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,11]]},"DOI":"10.7759\/cureus.89851","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T06:57:49Z","timestamp":1754981869000},"source":"Crossref","is-referenced-by-count":0,"title":["Transthyretin-Related Cardiac Amyloidosis: A Case of Delayed Diagnosis in the Comorbid Patient and Literature Review"],"prefix":"10.7759","author":[{"given":"Akshaye","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immy","family":"Stringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyan","family":"Edhem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gedoni","family":"Eni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Delamere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhiamluka","family":"Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.111.000364","article-title":"Updates in cardiac amyloidosis: a review","volume":"1","author":"Banypersad SM","year":"2012","unstructured":"Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012, 1:e000364. 10.1161\/JAHA.111.000364","journal-title":"J Am Heart Assoc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore JD","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, et al.. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018, 39:2799-806. 10.1093\/eurheartj\/ehx589","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore JD","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al.. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016, 133:2404-12. 10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez E","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, et al.. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015, 36:2585-94. 10.1093\/eurheartj\/ehv338","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen M","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, et al.. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008, 40:232-9. 10.1080\/07853890701842988","journal-title":"Ann Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock TP","year":"2018","unstructured":"Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018, 2:1046-53. 10.1182\/bloodadvances.2018016402","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson MM","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, et al.. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020, 142:e7-e22. 10.1161\/CIR.0000000000000792","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2003.50118","article-title":"B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study","volume":"41","author":"McCullough PA","year":"2003","unstructured":"McCullough PA, Duc P, Omland T, et al.. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003, 41:571-9. 10.1053\/ajkd.2003.50118","journal-title":"Am J Kidney Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane T","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, et al.. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019, 140:16-26. 10.1161\/CIRCULATIONAHA.118.038169","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac amyloidosis: overlooked, underappreciated, and treatable","volume":"71","author":"Rubin J","year":"2020","unstructured":"Rubin J, Maurer MS. Cardiac amyloidosis: overlooked, underappreciated, and treatable. Annu Rev Med. 2020, 71:203-19. 10.1146\/annurev-med-052918-020140","journal-title":"Annu Rev Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari A","year":"2023","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023, 118:3517-35. 10.1093\/cvr\/cvac119","journal-title":"Cardiovasc Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.05.039","article-title":"Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology","volume":"128","author":"Maurer MS","year":"2015","unstructured":"Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am J Med. 2015, 128:1275-80. 10.1016\/j.amjmed.2015.05.039","journal-title":"Am J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2024.07.005","article-title":"Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study","volume":"78","author":"Garc\u00eda-Pav\u00eda P","year":"2025","unstructured":"Garc\u00eda-Pav\u00eda P, Garc\u00eda-Pinilla JM, Lozano-Bahamonde A, et al.. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study. Rev Esp Cardiol (Engl Ed). 2025, 78:301-10. 10.1016\/j.rec.2024.07.005","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111519","article-title":"Heart failure with preserved ejection fraction and cardiac amyloidosis in the aging heart","volume":"25","author":"Tana M","year":"2024","unstructured":"Tana M, Piccinini R, Moffa L, Tana C. Heart failure with preserved ejection fraction and cardiac amyloidosis in the aging heart. Int J Mol Sci. 2024, 25:9. 10.3390\/ijms252111519","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko L","year":"2020","unstructured":"Chacko L, Martone R, Bandera F, et al.. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J. 2020, 41:1439-47. 10.1093\/eurheartj\/ehz905","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk RH","year":"2005","unstructured":"Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005, 112:2047-60. 10.1161\/CIRCULATIONAHA.104.489187","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.52.3.321","article-title":"Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy","volume":"52","author":"Eriksson P","year":"1984","unstructured":"Eriksson P, Backman C, Bjerle P, Eriksson A, Holm S, Olofsson BO. Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br Heart J. 1984, 52:321-6. 10.1136\/hrt.52.3.321","journal-title":"Br Heart J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1985.tb01630.x","article-title":"Highly refractile myocardial echoes in familial amyloidosis with polyneuropathy: a correlative echocardiographic and histopathological study","volume":"217","author":"Eriksson P","year":"1985","unstructured":"Eriksson P, Eriksson A, Backman C, Hofer PA, Olofsson BO. Highly refractile myocardial echoes in familial amyloidosis with polyneuropathy: a correlative echocardiographic and histopathological study. Acta Med Scand. 1985, 217:27-32. 10.1111\/j.0954-6820.1985.tb01630.x","journal-title":"Acta Med Scand"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan E","year":"2020","unstructured":"Donnellan E, Wazni OM, Saliba WI, et al.. Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis. Am J Cardiol. 2020, 128:140-6. 10.1016\/j.amjcard.2020.05.021","journal-title":"Am J Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari A","year":"2022","unstructured":"Porcari A, Rossi M, Cappelli F, et al.. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022, 24:1227-36. 10.1002\/ejhf.2533","journal-title":"Eur J Heart Fail"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112888","article-title":"Arrhythmic burden in cardiac amyloidosis: what we know and what we do not","volume":"10","author":"Argir\u00f2 A","year":"2022","unstructured":"Argir\u00f2 A, Del Franco A, Mazzoni C, et al.. Arrhythmic burden in cardiac amyloidosis: what we know and what we do not. Biomedicines. 2022, 10:8. 10.3390\/biomedicines10112888","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/397564-transthyretin-related-cardiac-amyloidosis-a-case-of-delayed-diagnosis-in-the-comorbid-patient-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T06:57:50Z","timestamp":1754981870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/397564-transthyretin-related-cardiac-amyloidosis-a-case-of-delayed-diagnosis-in-the-comorbid-patient-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.89851","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,11]]}}}